Table Of Content

VOL. 30, NO. 4, 1994 Cumulative Table of Contents Psychopharmacology Bulletin Vol. 30, No. 1—1994 NCDEU 1993 Annual Meeting— SHT,, Receptors and Pharmacotherapy Papers and Abstracts 39 Is Serotonin Receptor Down-Regulation Linked to the Mechanism of Action of Design and Methodology Issues for Antidepressant Drugs?—Stephen Stahl Clinical Treatment Trials in Children and Adolescents Dysthymia and Chronic Depressive States: 3 Child and Adolescent Psychopharmacology: Diagnostic and Pharmacotherapeutic Expanding the Research Base—Peter S. Considerations Jensen, Benedetto Vitiello, Henrietta Leonard, and Thomas P. Laughren 45 Overview of the Diagnosis, Prevalence, and Comorbidity of Dysthymia—Harry E. Federal Medications Development Gwirtsman Programs: A Novel Approach to Providing Needed Pharmacotherapies 53 Psychopharmacological Treatment Response of Patients with a DSM-III Diagnosis of Dysthymic Disorder—David ‘9 = Introduction—Frederick K. Goodwin Bakish, Arun Ravindran, Cynthia Hooper, and Yvon Lapierre 15 Alzheimer’s Disease Drug Development and Testing at the National Institute on Aging—Neil S. Buckholtz Commentary 19 The National Institute of Mental Health- Psychotherapeutic Medications 61 Screening and Evaluating Alternative and Development Program (PMDP): Status Innovative Psychiatric Treatments: A 1993—Henry J. Haigler Contextual Framework—L. Eugene Arnold Psychotropic Drug Labeling: Regulatory, Pharmaceutical Industry, and Clinical NCDEU Abstracts—1993 Annual Meeting Issues and Perspectives 71 1993 NCDEU Free Communications 23 A Pharmaceutical Industry Perspective on (in alphabetical order by first author) Drug Labeling—Donald S. Robinson 85 1993 NCDEU Poster Sessions NCDEU Update (in alphabetical order by first author) 27 = Treatment of Bipolar Disorder: How Far Have We Come?—Heather Stone Hopkins and Alan J. Gelenberg PSYCHOPHARMACOLOGY BULLETIN Vol. 30, No. 2—1994 Posters and Free Communications - 179 A Comparison of Delusional and 1993 NCDEU Meeting Nondelusional Body Dysmorphic Disorder in 100 Cases—Katharine A. Phillips, Depression Susan L. McElroy, Paul E. Keck, Jr., James I. Hudson, and Harrison G. Pope, Jr. 145 Metabolic and Physiologic Consequences of Nortriptyline Treatment in the Elderly— Schizophrenia Bruce G. Pollock, JamesM . Perel, Cynthia F. Paradis, Amy L. Fasiczka, and Charles 187 Early Course of New-Onset Tardive F. Reynolds III Dyskinesia in Older Patients—Jonathan P. Lacro, Patricia L. Gilbert, Jane S. Paulsen, 151 Are Selective Serotonin Reuptake Inhibitors Robert Fell, Anne Bailey, Charles Juels, Well Tolerated in Somatizing Depressives? Michael Caligiuri, Lou Ann McAdams, —Robert D. Linden, Charles S. Wilcox, M. Jackuelyn Harris, and Dilip V. Jeste Jon F. Heiser, Elaine Cavanaugh, and Peter G. Wisselink 193 Pharmacokinetics of Risperidone in Chronic Schizophrenic Patients— Richard 157 The Antidepressant Response to Tricyclics L. Borison, Bruce Diamond, Ananda in Major Depressives Is Accelerated With Pathiraja, and Richard C. Meibach Adjunctive Use of Methylphenidate— Harry E. Gwirtsman, Martin P. Szuba, 199 = Scales for the Assessment of Neuroleptic Lili Toren, and Michael Feist Response in Schizophrenic Children: Specific Measures Derived From the 165 Long-Term Treatment of Depression With CPRS—Elizabeth Kay Spencer, Murray Nefazodone—Susan F. Anton, Donald S. Alpert, and Enrique R. Pouget Robinson, Douglas L. Roberts, Terry T. Kensler, Patricia A. English, and Donald G. Archibald Childhood-Onset Disorders Anxiety and Related Disorders 203 Naltrexone Plasma Levels, Clinical Response and Effect on Weight in 171 Dose-Response Characterization of the Autistic Children—Nilda M. Gonzalez, Antipanic Effects of Imipramine—Matig Magda Campbell, Arthur M. Small, R. Mavissakalian and James M. Perel Judith Shay, Lisa D. Bluhm, Phillip B. Adams, and Rodger L. Foltz 175 Discriminating Placebo and Drug in Generalized Anxiety Disorder (GAD) 209 Placebo Response in Aggressive Children Trials: Single vs. Multiple Clinical Raters— With Conduct Disorder—Laura E. Vincent Glaudin, Ward T. Smith, James M. Sanchez, Jorge L. Armenteros, Arthur Ferguson, Eugene A. DuBoff, Murray H. M. Small, Magda Campbell, and Phillip Rosenthal, and Denis Mee-Lee B. Adams VOL. 30, NO.4 , 1994 741 215 The Overt Aggression Scale in a Study of Additional Topics Lithium in Aggressive Conduct 239 Disorder—Richard P. Malone, James Clinical Sequelae of Overt Noncompliance Luebbert, Maria Pena-Ariet, Krista With Psychotropic Agents—Robert A. Biesecker, and Mary Anne Delaney Littrell, Arch G. Mainous III, Fred Karem, Jr., W. Russell Coyle, and Chad M. 219 Effects of Intravenous Dextroamphetamine Reynolds on Brain Metabolism in Adults With 245 Attention-Deficit Hyperactivity Disorder Self-Injurious Behavior and Serotonin in (ADHD). Preliminary Findings—Monique Prader-Willi Syndrome—VJessica A. Ernst, Alan J. Zametkin, John A. Hellings and Julia K. Warnock Matochik, Laura Liebenauer, Glinda A. Fitzgerald, and Robert M. Cohen Commentary Statistical Analysis 251 Inhibition of Hepatic P-450 Isoenzymes by Serotonin Selective Reuptake Inhibitors: 227 The Resampling Method of Statistical In Vitro and In Vivo Findings and Their Analysis—Simcha Pollack, Peter Bruce, Implications for Patient Care—Sheldon H. Michael Borenstein, and Jeffrey Preskorn and Ryan D. Magnus Lieberman 235 A Note on the Use of Confidence Intervals in Psychiatric Research—Michael Borenstein PSYCHOPHARMACOLOGY BULLETIN Vol. 30, No. 3—1994 New Directions for ECT Research 471 Patient Attitudes Toward Electrocon- vulsive Therapy—Helen M. Pettinati, 265 Introduction—Frederick K. Goodwin Traci A. Tamburello, Charles R. Ruetsch, and Frances N. Kaplan 269 Indications for the Use of ECI—Max Fink 477 The Role of Structural Brain Imaging in ECT—C. Edward Coffey 276 Group Discussion 485 The Thyroid and Electroconvulsive 281 Central Issues Regarding The Treatment—Russell T. Joffe and Mechanisms of Action of Electrocon- Stephen T.H. Sokolov vulsive Therapy: Directions for Future Research—Harold A. Sackeim 489 Effects of Electroconvulsive Therapy on the CRH-ACTH-Cortisol System in The Mode of Action of ECT—Max Fink Melancholic Depression: Preliminary Findings—MitchelA . Kling, Thomas D. 313 Treatment Optimization With ECT— Geracioti, Julio Licinio, David Richard D. Weiner Michelson, Edward H. Oldfield, and Philip W. Gold 321 Animal Studies of Electroconvulsive Therapy: Foundations for Future Research—Laura J. Fochtmann 495 Electroconvulsive Therapy and Parkin- son’s Disease: The Case for Further 445 Elucidation of Biochemical Basis of the Study—Charles H. Kellner, Mark D. Antidepressant Action of Electrocon- Beale, John T. Pritchett, Hilary J. vulsive Therapy by Human Studies— Bernstein, and Carol M. Burns J. John Mann and Shitij Kapur 501 455 Continuation Therapy Following ECT: ECT Methodologic Issues— William Z. Directions for Future Research—Harold Potter A. Sackeim 461 Neuropsychology and ECT: Past and Future Research Trends—A vraham Calev VOL. 30, NO. 4, 1994 743 Vol. 30, No. 4—1994 Psychotherapeutic Medications 567 Developmental Aspects of NMDA Receptor Development Program (PMDP) Agonists and Antagonists in the Central Nervous System—Michael V. Johnston Workshop on NMDA Receptor Antagonists: Neurotoxicity 577 Pathological Effects of MK-801 in the Rat Evaluation Posterior Cingulate/Retrosplenial Cortex— Andrew S. Fix 523 Editor’s Note—Matthew V. Rudorfer 585 Assessing Structural Changes in the Brain To Evaluate Neurotoxicological Effects of 525 Foreword: Psychotherapeutic Medications NMDA Receptor Antagonists—Roland N. Development Program (PMDP) Workshop Auer on NMDA Receptor Antagonists: Neurotoxicity Evaluation—Henry J. 593 Introduction to Principles and Procedures in Haigler Behavioral Testing—Deborah C. Rice 527 Introduction—Paul Leber 601 The Impact of NMDA Receptor Antagonists on Learning and Memory Functions— 533 Neurotoxicity of NMDA Receptor Deborah A. Cory-Slechta Antagonists: An Overview—John W. Olney 613 Acute Behavioral Toxicity of MK-801 and 541 Confocal Microscopic Visualization of MK- Phencyclidine: Effects on Rhesus Monkey 801-Induced Cytoplasmic Vacuoles in Performance in an Operant Test Battery— Vitro—Jennifer K. Freeman and Mark P. Merle G. Paule Goldberg Abstracts from the National 549 Biochemical Analysis of Glial Fibrillary Institute of Mental Health (NIMH)- Acidic Protein as a Quantitative Approach to Neurotoxicity Assessment: Advantages, sponsored New Clinical Drug Disadvantages and Application to the Evaluation Unit (NCDEU) Meeting Assessment of NMDA Receptor Antagonist- Induced Neurotoxicity—James P. 623 O'Callaghan Introduction 625 555 Neuronal Injury Produced By NMDA Free Communications Antagonists Can Be Detected Using Heat 645 Shock Proteins and Can Be Blocked With Poster Sessions Antipsychotics—F.R. Sharp, M. Butman, K Aardalen, J. Nickolenko, R. Nakki, 1994 Cumulative Table of Contents S.M. Massa, R.A. Swanson, and S.M. Sagar 1994 Cumulative Author Index 561 Effects of NMDA Receptor Antagonists on the Developing Brain—Martha Constantine-Paton 1994 Cumulative Keyword Index